AI Summary

An 18‑year‑old Senegalese patient with severe sickle‑cell disease is being treated with hydroxyurea produced by a local laboratory. The lab has begun manufacturing a generic version of the drug, marking the first time hydroxyurea is produced in Africa. By creating an affordable supply, the effort aims to lessen the disease’s impact and reduce treatment costs for patients across the continent.

AI summaries can be wrong sometimes—always verify important details using the source article.